PL1940349T3 - Preparat aerozolowy do inhalacji beta agonistów - Google Patents

Preparat aerozolowy do inhalacji beta agonistów

Info

Publication number
PL1940349T3
PL1940349T3 PL06807028T PL06807028T PL1940349T3 PL 1940349 T3 PL1940349 T3 PL 1940349T3 PL 06807028 T PL06807028 T PL 06807028T PL 06807028 T PL06807028 T PL 06807028T PL 1940349 T3 PL1940349 T3 PL 1940349T3
Authority
PL
Poland
Prior art keywords
inhalation
aerosol formulation
beta agonists
agonists
beta
Prior art date
Application number
PL06807028T
Other languages
English (en)
Inventor
Barbara Niklaus-Humke
Michael Nowak
Kirsten Radau
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1940349(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL1940349T3 publication Critical patent/PL1940349T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL06807028T 2005-10-10 2006-10-06 Preparat aerozolowy do inhalacji beta agonistów PL1940349T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10
EP06807028.3A EP1940349B1 (de) 2005-10-10 2006-10-06 Aerosolformulierung für die inhalation von betaagonisten
PCT/EP2006/067126 WO2007042468A2 (de) 2005-10-10 2006-10-06 Aerosolformulierung für die inhalation von betaagonisten

Publications (1)

Publication Number Publication Date
PL1940349T3 true PL1940349T3 (pl) 2018-07-31

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06807028T PL1940349T3 (pl) 2005-10-10 2006-10-06 Preparat aerozolowy do inhalacji beta agonistów

Country Status (31)

Country Link
US (3) US20070088030A1 (pl)
EP (1) EP1940349B1 (pl)
JP (1) JP2009511542A (pl)
KR (1) KR20080059290A (pl)
CN (1) CN101282712A (pl)
AR (1) AR058082A1 (pl)
AU (1) AU2006301330B9 (pl)
BR (1) BRPI0617278A2 (pl)
CA (1) CA2624786C (pl)
CY (1) CY1120199T1 (pl)
DK (1) DK1940349T3 (pl)
EA (1) EA200800927A1 (pl)
EC (1) ECSP088294A (pl)
ES (1) ES2668364T3 (pl)
HR (1) HRP20180713T1 (pl)
HU (1) HUE039186T2 (pl)
IL (1) IL190682A (pl)
LT (1) LT1940349T (pl)
MY (1) MY163503A (pl)
NO (1) NO343363B1 (pl)
NZ (1) NZ567545A (pl)
PE (1) PE20070708A1 (pl)
PL (1) PL1940349T3 (pl)
PT (1) PT1940349T (pl)
RS (1) RS57085B1 (pl)
SI (1) SI1940349T1 (pl)
TW (1) TWI389692B (pl)
UA (1) UA99250C2 (pl)
UY (1) UY29844A1 (pl)
WO (1) WO2007042468A2 (pl)
ZA (1) ZA200801390B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
EP1917253B1 (de) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
US20110319402A1 (en) * 2008-11-21 2011-12-29 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
JP2012509299A (ja) * 2008-11-21 2012-04-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング β作用薬吸入用のエアロゾル製剤
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014056840A1 (en) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3297607B1 (en) * 2015-05-18 2020-07-22 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN115703121A (zh) * 2021-08-07 2023-02-17 广州谷森制药有限公司 一种含噻托溴铵、奥达特罗药品制剂和除醛包材容器的组合
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
HUP0300832A2 (hu) 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
EP1781298B1 (de) * 2004-04-22 2012-01-04 Boehringer Ingelheim International GmbH Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists

Also Published As

Publication number Publication date
WO2007042468A2 (de) 2007-04-19
AU2006301330A1 (en) 2007-04-19
AR058082A1 (es) 2008-01-23
TWI389692B (zh) 2013-03-21
ES2668364T3 (es) 2018-05-17
RS57085B1 (sr) 2018-06-29
HUE039186T2 (hu) 2018-12-28
KR20080059290A (ko) 2008-06-26
IL190682A (en) 2015-06-30
EP1940349B1 (de) 2018-02-14
LT1940349T (lt) 2018-05-10
UA99250C2 (ru) 2012-08-10
IL190682A0 (en) 2008-11-03
US20110190284A1 (en) 2011-08-04
UY29844A1 (es) 2007-05-31
CY1120199T1 (el) 2018-12-12
WO2007042468A3 (de) 2007-08-02
NZ567545A (en) 2011-07-29
AU2006301330B2 (en) 2012-11-22
ECSP088294A (es) 2008-04-28
EP1940349A2 (de) 2008-07-09
DK1940349T3 (en) 2018-05-28
US20070088030A1 (en) 2007-04-19
MY163503A (en) 2017-09-15
ZA200801390B (en) 2009-01-28
CA2624786A1 (en) 2007-04-19
TW200730178A (en) 2007-08-16
AU2006301330B9 (en) 2013-01-17
JP2009511542A (ja) 2009-03-19
US20100009984A1 (en) 2010-01-14
PE20070708A1 (es) 2007-08-06
CN101282712A (zh) 2008-10-08
HRP20180713T1 (hr) 2018-06-15
BRPI0617278A2 (pt) 2011-07-19
CA2624786C (en) 2015-06-16
EA200800927A1 (ru) 2008-10-30
SI1940349T1 (en) 2018-05-31
PT1940349T (pt) 2018-04-30
NO343363B1 (no) 2019-02-11
NO20080801L (no) 2008-04-29

Similar Documents

Publication Publication Date Title
ZA200801390B (en) Aerosol formulation for the inhalation of beta agonists
IL197025A0 (en) Aerosol formulation for the inhalation of beta agonists
IL197024A0 (en) Aerosol formulation for the inhalation of beta agonists
IL191809A0 (en) Powder compositions for inhalation
IL188290A (en) Hand piece for the delivery of light
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
IL189856A0 (en) New formulation
ZA200808531B (en) Pharmaceutical composition for external use
HUE026549T2 (hu) 1-N-azacikloalkil-3-fenoxipropán pszichotróp gyógyszerek elõállítására alkalmas származékai
IL198854A0 (en) Powder formulation for valganciclovir
IL194961A0 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
ZA200806929B (en) Nebulizer formulation
TWI370115B (en) New formulation
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
GB0508152D0 (en) Aerosol insecticide composition
IL179218A0 (en) Aerosol formulation for inhalation of beta agonists
PT2167042E (pt) Composições de aerossóis farmacêuticas compreendendo fluticasona
ZA200900370B (en) Aerosol formulation for the inhalation of beta agonists
GB0501956D0 (en) Nebulizer formulation
EP1852117A4 (en) SOLIFENACIN CONTAINING PHARMACEUTICAL AGENT
ZA200900418B (en) Aerosol formulation for the inhalation of beta agonists
ZA200606181B (en) Aerosol formulation
GB0519083D0 (en) Compositions for the improved delivery of medicaments
PL376552A1 (pl) Środek do zwalczania zagrożeń pyłowych